Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,961 total articles
Chris Koopmans, President and Chief Operating Officer at Marvell Technology, Inc., executed a sale of company stock totaling $2.06 million on June 1, 2026. This transaction occurred while the company's stock was trading near its 52-week high. Despite the executive selling shares, recent analyst reports have maintained or increased price targets for…
Chief Operating Officer John R. Gallagher executed a sale of Trupanion, Inc. (NASDAQ:TRUP) common stock totaling $78,153 on May 28, 2026. This transaction was conducted through a pre-arranged Rule 10b5-1 trading plan for financial diversification. Despite the insider activity and the stock trading near its 52-week low of $21.16 (down 52% over the l…
Gregory S. Moss, Chief Business & Legal Officer at Evommune, Inc., executed a significant sale of company shares while simultaneously acquiring additional stock through employee option exercises. This insider activity occurred as the company prepares for its earnings report on June 10th. Recent developments include the firm reporting a first-quarte…
The recent sale of shares by Evommune's CFO, Kyle Carver, provides an analytical snapshot of internal activity. The transaction occurred within a pre-arranged Rule 10b5-1 trading plan, while the company navigates both strong financial metrics and differing market valuation assessments. Furthermore, recent clinical trial progress and analyst upgrade…
Director Mark Garrett recently executed significant stock transactions involving the sale of shares, while simultaneously acquiring others. These personal movements occur against a backdrop of robust company financials for the first quarter of fiscal 2027. The reported earnings details, which included substantial year-over-year growth in product re…
Snowflake Director Frank Slootman recently conducted significant stock transactions, selling approximately $110.3 million worth of shares after exercising options. These sales occurred against a backdrop of strong company performance, as Snowflake reported impressive first-quarter fiscal 2027 results, with product revenue reaching $1.334 billion an…
Entities associated with Stadium Capital Management LLC reported a substantial sale of Sleep Number Corp (SNBR) common stock on May 28, 2026. This transaction occurred against a backdrop of declining stock performance for SNBR, which is currently trading at $1.24 and reflecting an 85% year-to-date decline. Furthermore, the company recently reported…
Director Lynn Jurich sold a significant block of Sunrun shares following the adoption of a Rule 10b5-1 trading plan. This activity occurred against a backdrop of robust financial performance for the first quarter of 2026, where the company significantly beat analyst expectations on both earnings per share and revenue.
David Soergel, the Chief Medical Officer at Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), recently sold a block of company shares. This transaction occurred despite recent positive developments for the firm, including robust quarterly earnings and significant clinical data presentations regarding its drug candidate, Rezdiffra.The sale involved 1,0…
Jeffrey Dell, Chief Information Officer at Red Violet, Inc., executed a series of sales totaling 10,000 shares of the company's common stock on June 1, 2026. These transactions generated an approximate value of $574,350. The sale occurred while the underlying stock has experienced significant upward momentum and some analysis suggests it may be tra…
Scott H. Keeney, the President and Chief Executive Officer of nLIGHT, Inc., recently executed significant stock sales and made a charitable donation of shares. These personal transactions occurred against a backdrop of strong financial reporting for the first quarter of 2026, where the company surpassed analyst expectations and saw major increases …
Derek Dubner, the Chief Executive Officer and Chairman of the Board at Red Violet, Inc. (NASDAQ:RDVT), recently executed a sale of company shares totaling $689,160. This transaction occurred on June 1, 2026, involving 12,000 common stock shares. The sale takes place against a backdrop where the stock has appreciated by 17% over the past week and is…
The Chief Financial Officer of Red Violet, Inc. (NASDAQ:RDVT), Daniel MacLachlan, reported selling common stock totaling $689,160 on June 1, 2026. This transaction occurred as the company's stock had risen significantly over the past week and is currently trading above its indicated Fair Value. Separately, Red Violet announced robust financial resu…
Alexander Azoy, Chief Accounting Officer at Arcus Biosciences, Inc., sold a portion of his holdings in the biotechnology firm. This transaction occurred while the company's stock has experienced significant gains and reported first quarter financials that fell short of market expectations. Analysts remain active, with one firm raising its price tar…
Alphabet director Frances Arnold sold 102 shares of Class C Capital Stock on May 29, 2026, for a total value of $38,862. This sale was executed through a Rule 10b5-1 trading plan adopted by Arnold on August 21, 2025. The transaction occurs against the backdrop of strong performance metrics and significant industry developments, including major loan…
Howard Horn, the Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), executed a transaction involving the disposal of company stock valued at $110,601 on June 1, 2026. This activity occurred while the stock traded significantly below its recent high. Meanwhile, the company reported first-quarter losses that missed analyst expec…
The recent sale of company stock by WEX Inc.'s Chief Operating Officer, Robert Joseph Deshaies, has occurred amidst a period of significant positive corporate developments. Mr. Deshaies sold 1,200 shares valued at $173,808 on May 28, 2026. This transaction takes place against a backdrop of WEX reporting strong first-quarter financial results and an…
Executive Vice President Andrew Callos sold a total value of $1.11 million in Cytokinetics common stock after utilizing exercised options. This transaction occurred against a backdrop of significant corporate activity for the company, including the German market entry of its heart drug Myqorzo and multiple large-scale capital offerings.
Cytokinetics' director, Edward M. Kaye, recently sold a substantial block of shares in the company's common stock. This transaction occurs against a backdrop of positive corporate developments for Cytokinetics Inc., including the launch of its heart drug Myqorzo in Germany, recent successful public offerings raising significant capital, and an elev…
Cytokinetics announced a significant commercial milestone with the market entry of its heart drug, Myqorzo, in Germany. These developments coincide with recent insider activity, including a director sale, and substantial financial fundraising efforts that underscore the company's current operational momentum and strategic planning.
A recent SEC Form 4 filing details the sale of company common stock by AAON director Gary D. Fields, totaling $2,663,800. The transaction occurs amid strong market performance for AAON, which reported better-than-expected first-quarter results and raised its full-year guidance. Analysts are also noting that the stock appears overvalued relative to …
Jonathan P. Faust, Executive Vice President and Chief Financial Officer at SANMINA CORP (NASDAQ:SANM), executed transactions totaling $2.67 million on May 29, 2026. This selling activity occurred against a backdrop of strong corporate performance, with Sanmina reporting an EPS of $3.16 and revenue reaching $4.01 billion for Q2 fiscal year 2026. The…
EnerSys's Chief Financial Officer, Andrea J. Funk, recently purchased a notable amount of the company's common stock. This insider activity occurs against a backdrop of positive corporate performance, including recent earnings that beat expectations and guidance suggesting continued momentum. However, analysis also points to valuation concerns, wit…
A collective disposal of approximately $1.16 billion worth of Medline Inc.'s (MDLN) Class A Common Stock occurred on May 28, 2026, through an underwritten public offering involving Hellman & Friedman affiliated funds. The transaction included the sale of 31,868,237 shares at a specific price point, followed by in-kind distributions to ultimate part…
Protagonist Therapeutics director William D. Waddill executed a sale of company common stock on May 29, 2026, using pre-arranged trading plans. This transaction occurred against a backdrop of significant analyst upgrades and positive projections for the firm's product platform, particularly Icotyde.
